1. Home
  2. Analysis
  3. Vimizim
  4. Infusion-site-pain

Vimizim and Infusion site pain - a phase IV clinical study of FDA data

Summary:

Infusion site pain is reported as a side effect among people who take Vimizim (elosulfase alfa), especially for people who are female, 10-19 old, also take Acetaminophen,.

The phase IV clinical study analyzes which people have Infusion site pain when taking Vimizim. It is created by eHealthMe based on reports of 4,772 people who have side effects when taking Vimizim from the FDA, and is updated regularly.

What is Vimizim?

Vimizim has active ingredients of elosulfase alfa. eHealthMe is studying from 4,772 Vimizim users. Check the latest studies of Vimizim.

What is Infusion site pain?

Infusion site pain is found to be associated with 751 drugs and 465 conditions by eHealthMe. Check the latest studies of Infusion site pain.

On Jul, 19, 2026

4,772 people reported to have side effects when taking Vimizim.
Among them, 15 people (0.31%) have Infusion site pain.

Could Vimizim cause Infusion site pain?

Among these 15 people:

What is the gender of people who have Infusion site pain when taking Vimizim? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Infusion site pain when taking Vimizim? *

  • 0-1: 0.0 %
  • 2-9: 14.29 %
  • 10-19: 42.86 %
  • 20-29: 14.29 %
  • 30-39: 0.0 %
  • 40-49: 14.29 %
  • 50-59: 14.29 %
  • 60+: 0.0 %

What are other drugs people take besides Vimizim? *

  1. Acetaminophen: 2 people, 13.33%
  2. Vitamin D3: 1 person, 6.67%
  3. Amlodipine: 1 person, 6.67%
  4. Azelastine Hydrochloride: 1 person, 6.67%
  5. Benadryl: 1 person, 6.67%
  6. Calcium Carbonate: 1 person, 6.67%
  7. Cetirizine Hydrochloride: 1 person, 6.67%
  8. Epinephrine: 1 person, 6.67%
  9. Fluticasone Propionate: 1 person, 6.67%
  10. Vitamins: 1 person, 6.67%

What are other side effects people have besides Infusion site pain? *

  1. Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 3 people, 20.00%
  2. Vascular Access Complication: 2 people, 13.33%
  3. Crying: 2 people, 13.33%
  4. Infusion Site Swelling: 2 people, 13.33%
  5. Infusion Site Oedema (swelling from excessive accumulation of watery fluid from infusion site): 2 people, 13.33%
  6. Hallucination, Auditory (perceiving sounds without auditory stimulus): 1 person, 6.67%
  7. Catheter Site Swelling: 1 person, 6.67%
  8. Chest Pain: 1 person, 6.67%
  9. Clubbing Of The Fingers Or Toes (deformity of the fingers): 1 person, 6.67%
  10. Depression: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Vimizim and have Infusion site pain?

- Check whether Infusion site pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vimizim:

Infusion site pain treatments and more:

How severe was Infusion site pain and when was it recovered:

Expand to all the drugs that have ingredients of elosulfase alfa:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Vimizim:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site pain:

Browse all the conditions that are associated with Infusion site pain:

How the study uses the data?

The study uses data from the FDA. It is based on elosulfase alfa (the active ingredients of Vimizim) and Vimizim (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.